(Q42981780)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22742526%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

meta-analysis

0 references

title

Meta-analysis: the impact of IL28B polymorphisms on rapid and sustained virological response in HCV-2 and -3 patients (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22742526%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

0 references

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22742526%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

Eric Trépo

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22742526%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

Philippe Mathurin

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22742526%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

author name string

J Schreiber

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22742526%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

C Moreno

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22742526%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

B Garcia Garcia

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22742526%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

J Henrion

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22742526%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

D Thabut

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22742526%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

P Deltenre

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22742526%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

language of work or name

English

0 references

publication date

29 June 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22742526%20AND%20SRC:MED&resulttype=core&format=json

Alimentary Pharmacology & Therapeutics

6 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22742526%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

volume

36

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22742526%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22742526%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

page(s)

353-362

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22742526%20AND%20SRC:MED&resulttype=core&format=json

Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose

6 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2012.05197.X

Telaprevir for previously untreated chronic hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2012.05197.X

Boceprevir for untreated chronic HCV genotype 1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2012.05197.X

Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2012.05197.X

IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2012.05197.X

Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2012.05197.X

Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2012.05197.X

Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2012.05197.X

An IL28B polymorphism determines treatment response of hepatitis C virus genotype 2 or 3 patients who do not achieve a rapid virologic response

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2012.05197.X

Interleukin-28B genetic variants and hepatitis virus infection by different viral genotypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2012.05197.X

Predictive value of the IL28B polymorphism on the effect of interferon therapy in chronic hepatitis C patients with genotypes 2a and 2b.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2012.05197.X

Importance of IL28B gene polymorphisms in hepatitis C virus genotype 2 and 3 infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2012.05197.X

IL28B genetic variation and treatment response in patients with hepatitis C virus genotype 3 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2012.05197.X

Early virologic response and IL28B polymorphisms in patients with chronic hepatitis C genotype 3 treated with peginterferon alfa-2a and ribavirin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2012.05197.X

Role of interleukin-28B polymorphisms in the treatment of hepatitis C virus genotype 2 infection in Asian patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2012.05197.X

Meta-analyses of randomized controlled trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2012.05197.X

The retrieval of randomized clinical trials in liver disease from the medical literature. A comparison of MEDLARS and manual methods

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2012.05197.X

Meta-analysis in clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2012.05197.X

Bias in meta-analysis detected by a simple, graphical test

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2012.05197.X

Evaluation of amantadine in chronic hepatitis C: a meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2012.05197.X

Shortened treatment duration in treatment-naive genotype 1 HCV patients with rapid virological response: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2012.05197.X

Impact of insulin resistance on sustained response in HCV patients treated with pegylated interferon and ribavirin: a meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2012.05197.X

Ultra-rapid virological response, young age, low γ-GT/ALT-ratio, and absence of steatosis identify a subgroup of HCV Genotype 3 patients who achieve SVR with IFN-α(2a) monotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2012.05197.X

Complementary role of vitamin D deficiency and the interleukin-28B rs12979860 C/T polymorphism in predicting antiviral response in chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2012.05197.X

IL28B polymorphisms predict reduction of HCV RNA from the first day of therapy in chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2012.05197.X

Importance of host genetic factors HLA and IL28B as predictors of response to pegylated interferon and ribavirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2012.05197.X

Interferon-induced gene expression is a stronger predictor of treatment response than IL28B genotype in patients with hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2012.05197.X

IL28B polymorphisms, IP-10 and viral load predict virological response to therapy in chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2012.05197.X

IL28B rs12979860 C/T polymorphism in elderly chronic hepatitis C patients treated with pegylated-interferon and ribavirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2012.05197.X

A single IL28B genotype SNP rs12979860 determination predicts treatment response in patients with chronic hepatitis C Genotype 1 virus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2012.05197.X

Hepatic steatosis in chronic hepatitis C patients infected with genotype 2 is associated with insulin resistance, hepatic fibrosis and affects cumulative positivity of serum hepatitis C virus RNA in peginterferon and ribavirin combination therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2012.05197.X

Interleukin 28B gene variation at rs12979860 determines early viral kinetics during treatment in patients carrying genotypes 2 or 3 of hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2012.05197.X

IL-28B predicts response to chronic hepatitis C therapy--fine-mapping and replication study in Asian populations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2012.05197.X

Association of IL28B variants with response to pegylated-interferon alpha plus ribavirin combination therapy reveals intersubgenotypic differences between genotypes 2a and 2b.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2012.05197.X

Impact of IL28B genotype on the early and sustained virologic response in treatment-naïve patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2012.05197.X

Interferon-alfa, interferon-lambda and hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2012.05197.X

IL28B single nucleotide polymorphisms in the treatment of hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2012.05197.X

Insights into the role of interferon lambda in hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2012.05197.X

'Easy to treat' genotypes were not created equal: can rapid virological response (RVR) level the playing field?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2012.05197.X

Cell-type specific gene expression signature in liver underlies response to interferon therapy in chronic hepatitis C infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2012.05197.X

Hepatic gene expression during treatment with peginterferon and ribavirin: Identifying molecular pathways for treatment response

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2012.05197.X

Interferon signaling and treatment outcome in chronic hepatitis C

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2012.05197.X

Hepatic ISG expression is associated with genetic variation in interleukin 28B and the outcome of IFN therapy for chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2012.05197.X

IL28B genotype is associated with differential expression of intrahepatic interferon-stimulated genes in patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2012.05197.X

10.1111/J.1365-2036.2012.05197.X

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22742526%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

1 reference